Ten sesquiterpenoids (1-10) and six phenylpropanoid derivatives (11)(12)(13)(14)(15)(16) were isolated from the flower buds of Magnolia biondii Pamp. Their structures were determined by 1D-and 2D-NMR spectroscopy, mass spectrometry, and optical rotation. To evaluate their anti-allergic properties, the inhibitory effect of each isolate (1-16) on interleukin-2 (IL-2) gene expression was examined in Jurkat T cells. Among the isolated compounds, three sesquiterpenoids (2, 5, and 7) and two monoterpenoids (12 and 13) strongly inhibited IL-2 production in Jurkat T cells. Four compounds, (-)-parthenolide (2), eudesm-4(15)-eno-1β,6α-diol (5), biondinin D (12), and tiliroside (16), showed cytotoxicity against Jurkat T cells. In addition, (-)-parthenolide (2) exhibited cytotoxicity against the human cervical cancer HeLa cell line, the human breast cancer MCF-7, and human promyelocytic leukemia HL-60 cell lines.
Activated T cells have been implicated in the pathogenesis of a variety of autoimmune disorders such as atopic dermatitis, inflammatory bowel disease, and rheumatoid arthritis [1a] . Interleukin-2 (IL-2) is a lymphokine characterized biologically by its ability to maintain in vitro proliferation of activated T cells [1b] . Extensive research has reported that IL-2 plays a primary role in T cell-mediated allergic inflammation [1c,1d] .
The flower buds of Magnolia biondii Pamp. (Magnoliaceae) have been used in traditional medicine to treat headache and rhinitis in Korea and China [2a, 2b] . Phytochemical studies of this medicinal plant have resulted in the identification of various lignans, neolignans, sesquiterpenes, and phenolic compounds [2a-2d] .
To identify anti-allergic and anticancer compounds in the flower buds of M. biondii, the chloroform-and ethyl acetate (EtOAc)soluble fractions were sequentially fractionated using several column chromatography and high performance liquid chromatography (HPLC) to afford sixteen compounds (1-16). Further analysis by 1D-and 2D-NMR, mass spectrometry, and optical rotation identified ten of these compounds as sesquiterpenes: 1β,4β,6α-gorgonane-1,4,11-triol (4) [3d], eudesm-4(15)-eno-1β,6αdiol (5) (Figure 1 ). To our knowledge, this is the first report to isolate compounds 4-7, 9-11, 14, and 15 from M. biondii, and compound 9 from natural sources.
The anti-allergic effects of the compounds (1-16) were evaluated by determining their ability to inhibit IL-2 production in Jurkat T cells stimulated with PMA (200 nM) and A23187 (1 μM). Among the isolated compounds, three sesquiterpenoids (2, 5, and 7) and two monoterpenoids (12 and 13) strongly inhibited IL-2 production in Jurkat T cells (Figure 2A ).
In a previous study, it was reported that three sesquiterpene lactones, parthenolide, 11,13-dihydroparthenolide, and enhydrin, isolated from M. biondii possessed anti-inflammatory and antihyperalgesic effects [4] . In our study, two of the active sesquiterpenoids (5 and 7) have eudesmane-structure while (-)parthenolide (2) is a lactone ring bearing sesquiterpene. Meanwhile, the two monoterpenoids with anti-allergic effects, biondinin D (12) and biondinin C (13), possess a cinnamoyl moiety attached to the monoterpene unit (borneol), which is likely the active part of their structure that mediates their inhibitory activity against IL-2 production. To determine whether inhibition of IL-2 production is due to cellular toxicity, the cytotoxic effect of the compounds on Jurkat T cells was examined using the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetra-zolium bromide (MTT) assay according to the protocol described by Mosmann [5] . Only four compounds, (-)-Parthenolide (2), eudesm-4(15)-eno-1β,6α-diol (5), biondinin D (12), and tiliroside (16), showed cytotoxicity against Jurkat T cells ( Figure 2B ). Hence, the inhibitory effect of isoplodiol (7) and biondinin C (13) on IL-2 production in Jurkat T cells was not due to cytotoxicity. Consequently, the cytotoxicity of the compounds were evaluated in three human cancer cells lines, breast cancer (MCF-7), cervical cancer (HeLa), and promyelocytic leukemia (HL-60) cell line derived from the peripheral blood of a patient with acute promyelocytic leukemia. All three cell lines were treated with the isolated compounds (1-16) at concentrations of 5 and 50 μM. Adriamycin was used as the positive control. Results show that (-)parthenolide (2) exhibited the highest cytotoxic activity against Hela cells with an IC 50 value of 23.3 ± 2.8 μM, followed by MCF-7 and HL-60 cells, with IC 50 values of 27.9 ± 1.6 and 47.8 ± 2.5 μM, respectively ( Figure 2B ). Based on our results, we suggest that compound 2 could be useful for anti-allergic and cytotoxic agent with further mechanism study. 
Extraction and isolation:
Dried flower buds of M. biondii (9.0 kg) were extracted three times by refluxing with methanol (MeOH) (3 h × 4 L) at 60°C. The MeOH-soluble fraction was filtered and concentrated under vacuum to obtain brown residues (1.2 kg). The residues were dissolved in water and extracted by partitioning with organic solvents to obtain the chloroform (591.7 g), EtOAc (28.2 g), and aqueous (104.5 g) extracts. The chloroform-soluble extract was chromatographed on silica gel using vacuum liquid chromatography (VLC) (63 -200 μm particle size, Merck) and subjected to stepwise elution with a mixture of methylene chloride (MC) : hexane (3 : 7 → 1 : 0) and EtOAc : MC (1 : 99 → 1 : 19) to afford nine fractions (C-1 to C-9). Fraction C-4 (78.8 g) was chromatographed on silica gel using VLC and eluted with a mixture of 5 to 20 % acetone in hexane to yield six fractions (C4-1 to C4-6). Fraction C4-4 (15.4 g) was fractionated on silica gel column and eluted with a stepwise gradient of 55 to 60 % acetone in hexane to afford six fractions (C44-1 to C44-6). Fraction C44-3 (2.1 g) was applied to an RP-18 gel column and eluted with a mixture of MeOH and water (70 % → 80 %) to give compound 2 (100.2 mg). Fraction C-5 (53.0 g) was chromatographed over silica gel column and eluted stepwise with a mixture of 5 to 20 % acetone in hexane using VLC to afford seven fractions (C5-1 to C5-7). Fraction C5-4 (3.2 g) was subjected to RP-18 gel column chromatography using a mixture of MeOH in water (40 % → 50 %) to afford seven fractions (C54-1 to C54-7). Fraction C54-7 (600.1 mg) was chromatographed on silica gel column using an isocratic elution of 40 % hexane in MC to obtain compounds 1 (19.3 mg) and 4 (14.9 mg). Fraction C54-3 (1.3 g) was separated using RP-C18 column with a gradient elution of 50 to 70 % MeOH in water to afford nine fractions (C543-1 to C543-9). Fraction C543-7 (72.5 mg) was purified using preparative HPLC (YMC Pak ODS-A column, 20 × 250 mm, 5 μm, flow rate: 6 mL/min, 60 min) with a mobile phase composed of 88 % MeOH in water under isocratic elution to yield compounds 12 (18.8 mg, retention time (t R ) = 24.9 min) and 13 (21.9 mg, t R = 27.0 min). Fraction C5-5 (3.4 g) was separated on silica gel column and eluted with a mixture of 15 to 20 % EtOAc in hexane to yield six fractions (C55-1 to C55-6). Fraction C55-3 (940.8 mg) was subjected to RP-18 gel column chromatography with a mixture of MeOH in water (50 % → 60 %) to afford compound 3 (23.9 mg). Fraction C-9 (176.5 g) was fractionated on silica gel using VLC and eluted with a gradient mixture of 10 to 40 % acetone in hexane to obtain six fractions (C9-1 to C9-6). Fraction C9-1 (11.3 g) was chromatographed on silica gel column and eluted with a gradient mixture of 15 to 20 % acetone in hexane to yield seven fractions (C91-1 to C91-7). Fraction C91-6 (1.3 g) was applied to a silica gel column and eluted with a gradient mixture of 10 to 20 % acetone in hexane to yield nine fractions (C916-1 to C916-7). Fraction C916-1 (67.4 mg) was purified using preparative HPLC with a mobile phase comprising 85 % MeOH in water under isocratic elution to afford compounds 9 (1.2 mg, t R = 31.8 min) and 10 (2.6 mg, t R = 36.5 min). Fraction C916-5 (739.0 mg) was purified using preparative HPLC with 55 % acetonitrile in water under isocratic elution to afford compounds 7 (54.7 mg, t R = 20.0 min) and 8 (99.6 mg, t R = 22.4 min). Fraction C9-4 (7.8 g) was chromatographed on silica gel column and subjected to stepwise elution with a mixture of 10 to 40 % acetone in hexane to obtain eight fractions (C94-1 to C94-8). Fraction C94-5 (2.6 g) was subjected to RP-18 gel column chromatography with a mixture of MeOH in water (40 % → 50 %) to afford eight fractions (C945-1 to C945-7). Fraction C945-1 (180.1 mg) was purified using MCI gel column chromatography with a mixture of 50 to 80 % MeOH in water to afford compounds 6 (14.7 mg) and 11 (14.8 mg). Fraction C945-2 (293.5 mg) was purified using silica gel column chromatography with a mixture of 30 to 50 % acetone in hexane to give compound 4 (4.3 mg). The EtOAc-soluble (28.2 g) extract was chromatographed on a silica gel column using stepwise elution with 5 to 30 % MeOH in MC to yield nine fractions (E-1 to E-9). Fraction E-6 (4.3 g) was subjected to RP-18 gel column chromatography with a mixture of MeOH and water (30 % → 60 %) to afford compound 16 (464.4 mg) and seven other fractions (E6-1 to E6-7). Fraction E6-5 (105.8 mg) was subjected to RP-18 gel column and eluted with MeOH in water (30 % → 50 %) to Anti-allergic and cytotoxic effects of Magnolia biondii Natural Product Communications Vol. 12 (10) 2017 1545 obtain compound 15 (33.4 mg). Fraction E6-2 (590.8 mg) was separated by sephadex LH-20 column with 100 % MeOH to obtain compound 14 (3.4 mg).
Quantitative PCR and Real-time PCR:
Jurkat T cells (1 x 10 6 cells) were incubated with the compounds at the indicated concentrations for 30 min at 37 °C, followed by PMA (100 nM) and A23187 (1 μM) stimulation for 6 h. The cells were harvested, and total RNAs were isolated with TRIZOL reagent (JBI, Korea) and reverse transcribed using RT PreMix (enzynomics, Korea). Primer sequences for each gene and the PCR conditions used were as follows: human IL-2, 5′-CAC GTC TTG CAC TTG TCA C-3′ and 5′-CCT TCT TGG GCA TGT AAA ACT-3′; human GAPDH, 5′-CGG AGT CAA CGG ATT TGG TCG TAT-3′ and 5′-AGC CTT CTC CAT GGT GGT GAA GAC-3′. The amplification profile comprised of denaturation at 94°C for 30 s, annealing at 60°C for 20 s, and extension at 72°C for 40 s. The 30 cycles were preceded by denaturation at 72°C for 7 min. Real-time PCR was carried out in a total volume of 10 μL reaction mixture containing 1 μL of cDNA/control, gene specific primers, and SYBR Premix Ex Taq (Takara, Japan). Amplification was performed using DNA Engine Opticon1 continuous fluorescence detection system (MJ Research, Waltham, MA). PCR was carried out using the following conditions: 40 cycles at 94°C for 30 s, 60°C for 30 s, 72°C for 30 s, and plate read (detection of fluorescent product), followed by 7 min extension at 72°C. Melting curve analysis was performed to characterize the dsDNA product by slowly raising the temperature (0.2°C/s) from 65 to 95°C, and fluorescence data were collected at 0.2°C intervals. The IL-2 mRNA level was normalized to GAPDH and expressed as fold changes relative to that of untreated controls. Gene expression changes were calculated using the following equation: Fold change = 2 -ΔΔCT , where ΔΔCT = (CT value of target -CT value of GAPDH) at 24 h − (CT value of target -CT value of GAPDH) at 0 h, where 0 h represents the 1 × expression of the target gene in untreated cells normalized to GAPDH. All experiments were performed at least three times unless otherwise indicated.
Cell viability assay: Jurkat T cells (3 × 10 5 cells) were seeded in a 24-well plate. MCF-7, HeLa, and HL-60 cells were seeded at a density of 6 × 10 4 cells in 96-well plate and incubated with the compounds (1-16) at the indicated concentrations for 24 h. Thereafter, MTT solution (20 μL, 5 mg/ml) was added to the cells (180 μL) and the cells were further incubated for 2 h at 37°C. Following incubation, the cells were centrifuged and supernatants were removed. The resulting pellet was resuspended in 150 μL of DMSO and incubated for 15 min at room temperature. The absorbance was measured at 590 nm.
Statistical analysis:
Values are expressed as mean ± SD.
